Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CRVS News 21 January 2026

Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge

Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge

Corvus Pharmaceuticals shares rose 0.3% to $21.48 by midday after announcing a $150 million underwritten stock offering. The move follows positive Phase 1 results for soquelitinib in eczema, with 75% of treated patients achieving EASI-75 versus 20% on placebo. The company paused its $100 million at-the-market program and plans to use proceeds for R&D and ongoing trials.
21 January 2026
···
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
·····
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
21 January 2026
·····

Stock Market Today

Reckitt share price ends week near a one-year high as RKT investors eye special dividend and March results

Reckitt share price ends week near a one-year high as RKT investors eye special dividend and March results

7 February 2026
London, Feb 7, 2026, 08:16 GMT — Market closed. Reckitt Benckiser Group (RKT.L) shares ended Friday at 6,400 pence, down 0.2%, after touching a one-year high of 6,432 pence. About 2.6 million shares changed hands. (London South East) The stock is now trading through the tail-end of a chunky one-off cash return. Reckitt has set a 235 pence-a-share special dividend for Feb. 20 and is pairing it with a 24-for-25 share consolidation to keep the quoted share price and per-share metrics broadly comparable after the payout. (Investegate) In the wider market, Britain’s FTSE 100 finished Friday up 0.6%, with gains
GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop